Cibus (CBUS) EPS (Basic) (2016 - 2026)

Cibus (CBUS) posted EPS (Basic) of -$0.7 for Q4 2025, down 52.05% sequentially from -$0.46 in Q3 2025, and up 37.17% YoY from -$0.51 in Q4 2024.

Cibus (CBUS) EPS (Basic) (2016 - 2026) Analysis & Trends

Cibus has reported EPS (Basic) for 10 years, with the latest figure at -$0.7 in Q4 2025.

Quarterly EPS (Basic) rose 37.17% year-over-year to -$0.7 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$2.89 (up 76.27% YoY) and the FY2025 annual result came in at -$2.89, up 76.27% from the prior year.
EPS (Basic) declined to -$0.7 in Q4 2025 per CBUS's latest filing, from -$0.46 in the prior quarter.
Over five years, EPS (Basic) peaked at -$0.46 in Q3 2025 and troughed at -$26.88 in Q4 2023.
A 5-year average of -$5.56 and a median of -$3.21 in 2022 frame the typical range for EPS (Basic).
The sharpest annual moves came in 2023 and 2024: EPS (Basic) slumped 771.49% in 2023, then jumped 95.87% in 2024.
Over 5 years, EPS (Basic) stood at -$9.42 in 2021, then soared by 67.25% to -$3.08 in 2022, then slumped by 771.49% to -$26.88 in 2023, then surged by 95.87% to -$1.11 in 2024, then soared by 37.17% to -$0.7 in 2025.
According to Business Quant data, EPS (Basic) over the past three periods registered -$0.7, -$0.46, and -$0.64 for Q4 2025, Q3 2025, and Q2 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EPS (Basic) (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	4.34
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	12.62
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	7.59
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-1.96
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	2.12
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	1.23
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	-0.06
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	0.18
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	-0.72
10	Cibus	131.25 Mn	110.82 Mn	-	-0.29

Download Data